Clinical benefit and safety profile of darolutamide in patients who crossed over to darolutamide from placebo during the open-label period of the phase 3 ARAMIS study

Basit Öğe Kaydı
dc.contributor.authorTodenhoefer, Tilman
dc.contributor.authorFeyerabend, Susan
dc.contributor.authorShore, Neal
dc.contributor.authorSmith, Matthew
dc.contributor.authorKopyltsov, Evgeny
dc.contributor.authorAntonyan, Igor
dc.contributor.authorDamber, Jan-Erik
dc.date.accessioned2025-05-10T19:28:20Z
dc.date.issued2022
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstract[No abstract available]
dc.identifier.endpage106
dc.identifier.issn2296-5270
dc.identifier.issn2296-5262
dc.identifier.issueSUPPL 3
dc.identifier.scopusqualityQ3
dc.identifier.startpage106
dc.identifier.urihttps://hdl.handle.net/20.500.14730/7272
dc.identifier.volume45
dc.identifier.wosWOS:000883051700245
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherKarger
dc.relation.ispartofOncology Research and Treatment
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250302
dc.titleClinical benefit and safety profile of darolutamide in patients who crossed over to darolutamide from placebo during the open-label period of the phase 3 ARAMIS study
dc.typeConference Object

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu